Impact of Shot Blocker on Alleviating Peripheral Intravenous Cannulation Associated Pain among School-Aged Children: A Randomized Controlled Trial
Abstract
Background: The aim of this research is to examine the effectiveness of ShotBlocker in reducing pain to enhance school-age patients' experience with intravenous cannulation. Nurses need to explore non-pharmacological approaches during intravenous cannulation to pain management while adhering to ethical and legal principles. Objective: To investigate effectiveness of ShotBlocker and ShotBlocker placebo in reducing pain during intravenous cannulation in school age children’s patients. Methods: A Randomized Controlled Trial (RCT) that is comparative and prospective, was used. The study was conducted on 228 school age children’s patients (6-12 years) who undergo intravenous cannulation in Emergency Departments (EDs). Three groups of patients were randomly assigned: ShotBlocker group (n=79), ShotBlocker placebo group (n=75), and control group (n=74). The patients were requested to evaluate the level of pain immediately following Peripheral Intravenous Line (PIV) procedure using the Wong–Baker Faces Pain Scale. Results: This study showed P-value=0.000 indicated that there are statistically significant differences in pain intensity among the ShotBlocker, ShotBlocker placebo, and control groups. In comparison to both the ShotBlocker placebo and control group, the ShotBlocker group’s pain intensity was significantly reduced (mean difference 1.74684). Furthermore, there were higher pain levels noted in the ShotBlocker placebo (mean difference 8.50667) and control group (mean…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 228 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.